Young Israeli Data Scientist Develops AI Model to Predict Arthritis Flares
Data scientist Sapir Elad developed a 93% accurate machine learning model to predict autoimmune flare-ups after battling arthritis since age 14. Now leading Symptera, she is advancing clinical pilots.

Sapir Elad, a 25-year-old data scientist diagnosed with rheumatoid arthritis at age 14, is developing an innovative machine-learning model designed to predict the next flare-up of chronic autoimmune diseases. Living with severe physical limitations, joint swelling, and aggressive treatments including chemotherapy medications, Elad identified the psychological toll of chronic uncertainty as one of the most debilitating aspects of her condition.
Building a Predictive Algorithm at Home
Determined to eliminate the unpredictability of her condition, Elad utilized her master's degree and professional background in data science to build a predictive tool. Starting as a side project in her basement alongside her partner, she spent over a year developing a machine-learning model based on self-reported patient data. The initial results yielded a 93% accuracy rate, a rare achievement in complex medical data analysis.
Encouraged by early technical milestones, Elad entered the LaLaLand startup community, managed by Noam Maimon, and participated in a high-profile pitch night competition. Pitching her algorithm against established entrepreneurs managing revenue-generating businesses, Elad secured first place after generating immediate interest from prospective users and investment funds.
Transitioning to Commercial Development and Clinical Trials
Following her competition victory, Elad committed fully to the venture, leaving her previous job and entering the BASE 44 accelerator program. Her market validation research expanded to other chronic inflammatory conditions, including Crohn's disease and ulcerative colitis. The Symptera platform has since evolved to incorporate biometric metrics from wearable devices, with a beta version already tested by users.
Elad is currently preparing for clinical pilots in collaboration with medical centers and innovation hubs in Israel and the United States to validate the algorithm on broader patient populations.
"We are approaching our first pilot to verify that we can achieve the same accuracy rates on external patient populations through medical institutions and innovation centers we are in contact with," Elad stated.
The long-term objective is to commercialize the platform for hospitals and private clinics, enabling healthcare providers to monitor patient risk levels continuously and administer preventative interventions prior to acute symptom onset.





